8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes—2023
Open accessThe DOI matches its Crossref record; 128 of the 129 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and current guidelines recommend the use of GLP-1 receptor agonists in patients with diabetes who need cardiovascular risk reduction, weight management, or both. 38,39”
From Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (2023) · cites this paper as [39]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Weight management programmes have been shown to reduce the progression of type 2 diabetes, improve glycaemia, and reduce the need for glucose-lowering medications. 1”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
(2004) · The Lancet · doi:10.1016/s0140-6736(03)15268-3 · Cited by 12,717
Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., and the Northwell COVID-19 Research Consortium, Barnaby, D. P., Becker, L. B., Chelico, J. D., et al. (2020) · JAMA · doi:10.1001/jama.2020.6775 · Cited by 9,254
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668
Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery
Sjöström, L., Lindroos, A.-K., Peltonen, M., Torgerson, J., Bouchard, C., Carlsson, B., Dahlgren, S., Larsson, B., Narbro, K., Sjöström, C. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035622 · Cited by 4,457
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.025 · Cited by 3,418
Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes
Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Aminian, A., Brethauer, S. A., Navaneethan, S. D., Singh, R. P., Pothier, C. E., Nissen, S. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1600869 · Cited by 2,934
Research works printed but not linked: 1
- Wing, 2013, Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes, N Engl J Med, 369, 145, 10.1056/NEJMoa1212914 · DOI · Paper page
Cited by
Items 201–270 of 270
Risović, I., Djekic, D., Bojić, M., Markovic, A., Dojčinović, T., Vlatković, V., & Dobrovoljski, D. (2023) · Research Square · doi:10.21203/rs.3.rs-3340824/v1
TYPE 2 DIABETES AND BONE HEALTH: an epidemiological approach
Viggers, R. (2023) · VBN Forskningsportal (Aalborg Universitet) · doi:10.54337/aau561779793 · Cited by 1
El papel de la insulina en el tratamiento actual de la persona con diabetes mellitus tipo 2
Navarro, G. M., Ortega, M. M., & Biscari, N. C. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.insulinas.art1
Management of type 2 diabetes after metabolic bariatric surgery
Tham, K. W., & Lee, P. C. (2023) · Mini-invasive Surgery · doi:10.20517/2574-1225.2023.80 · Cited by 1
Olunusi, P. A., & Asunmo, M. R. (2023) · International Journal of Home Economics Hospitality and Allied Research · doi:10.57012/ijhhr.v2n2.016
Management of the child with obesity: Role and development of new medications
Martos‐Moreno, G. Á., & Argente, J. (2024) · Global Pediatrics · doi:10.1016/j.gpeds.2023.100126
Lopes, S., Maia, A., Melo, P., Abreu, S., Paiva, I., & Barros, L. (2024) · Acta Médica Portuguesa · doi:10.20344/amp.20858
Mid-Term Diabetes Remission Outcome in Patients with BMI ≤ 30 kg/m2 Following Sleeve Gastrectomy
Wang, J., Chu, Y., Hong, J., Zhu, X., Widjaja, J., & Yao, L. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07112-9
Achieving Effective Weight Loss for Type 2 Diabetes Mellitus Control: From Evidence to Practice
Chan, S. L. (2023) · The Singapore Family Physician · doi:10.33591/sfp.49.3.u2
Xu, X., Zhu, H., Wang, H., Zhu, X., Liu, L., Zhang, F., Zhou, H., Zhu, M., Dai, L., & Cai, L. (2024) · Aging · doi:10.18632/aging.205709 · Cited by 1
Aberle, J., Lautenbach, A., Meyhöfer, S., Meyhöfer, S. M., Menzen, M., Selig, L., Mai, K., & Blüher, M. (2024) · Die Diabetologie · doi:10.1007/s11428-024-01169-x
Creţoiu, S. M., Iancu, M. A., Condur, L., Salmen, T., Steriu, A., Stănescu, A. M. A., Eremia, I. A., Olariu, C. M., Cinteză, E. E., & Diaconu, C. C. (2024) · Journal of Mind and Medical Sciences · doi:10.22543/2392-7674.1451
“The assessment of abdominal fat tissue accumulation, either by measuring abdominal circumference or by calculating the waist/hip ratio, appears to be an independent predictor of the risk of high blood pressure [15,16].”
Cardiovascular Disease Risk and Risk Reduction Strategies in Diabetes Mellitus
Wilson, D. P., Hamilton, L., & Maki, K. C. (2024) · Contemporary cardiology · doi:10.1007/978-3-031-54960-1_14
Sustained Long-Term Significant Weight Reduction by Empagliflozin in an Adult Female Patient
Sinha, N. (2024) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_3_24
Current Approach of Diabetes Mellitus in Obese Patients
Karaburgu, S. (2023) · doi:10.69860/nobel.9786053359111.8
Current Nutritional Approaches in Diabetes Mellitus
Irgat, S. İ. (2023) · doi:10.69860/nobel.9786053359104.7 · Cited by 1
Technologies for Prevention of Diabetes Mellitus and Complications
Kesavadev, J., Basanth, A., & Jothydev, K. (2024) · Springer eBooks · doi:10.1007/978-981-97-6406-8_3 · Cited by 1
Rancang Bangun Aplikasi Monitor Kadar Gula Darah Berbasis Mobile
Zuhri, A., Hardiyanti, M., Fitriyani, N. L., & Alfian, G. (2024) · Journal of Internet and Software Engineering · doi:10.22146/jise.v5i2.9026
“Nilai BMI yang direkomendasikan adalah pada rentang 18,5-24,9 [30], [34].”
Adipose Tissue Dysfunction: Clinical Implications and Complications
Dronkers, J., Lobeek, M., Meems, L. M. G., & Gorter, T. M. (2024) · Contemporary Endocrinology · doi:10.1007/978-3-031-72570-8_5
Harnessing the Power of Nutraceuticals: A New Approach to Obesity Treatment
Monisha, D., Swathi, D. N., Deveswaran, R., & Basavaraj, B. V. (2024) · Journal of Pharmaceutical Research International · doi:10.9734/jpri/2024/v36i127635
Siahkouhian, M., Fasihi, L., & Ebrahimi-Torkamani, B. (2024) · Studies in Medical Sciences · doi:10.61186/umj.35.8.621
Namah, S., Esmael, W., & Abdul-Hussein, A. (2024) · Al-Kufa University Journal for Biology · doi:10.36320/ajb/v16.i3.15673 · Cited by 2
Aberle, J., Lautenbach, A., Meyhöfer, S., Menzen, M., Selig, L., Mai, K., Blüher, M., & Terkamp, C. (2025) · Diabetes aktuell · doi:10.1055/a-2539-0910
Comparative effects of 8-week exercise programs on fat reduction in female college students
Wang, D., & Ghani, D. Z. A. (2025) · Retos · doi:10.47197/retos.v68.111486
Bariatric and Metabolic Surgery for Type 2 Diabetes Reversal—Weighing Risks and Benefits
Pajtak, A., Špiranec, J. V., Senčar, M., & Štimac, D. (2025) · Bariatric Surgical Practice and Patient Care · doi:10.1089/bari.2025.0019
Aberle, J., Lautenbach, A., Meyhöfer, S., Menzen, M., Selig, L., Mai, K., Blüher, M., & Terkamp, C. (2025) · Die Diabetologie · doi:10.1007/s11428-025-01344-8
rahimi, S., & Barkhordari-Sharifabad, M. (2025) · Avicenna Journal of Nursing and Midwifery Care · doi:10.32592/ajnmc.33.2.173
Sobti, A. K., Singh, I., Subba, R., & Duggal, S. (2025) · Journal of Pharmacognosy and Phytochemistry · doi:10.22271/phyto.2025.v14.i4h.15521
Long, T., Zhang, Y., Wu, Y., Xing, P., Zhang, Y. H., & Li, M. (2025) · American Journal of Health Promotion · doi:10.1177/08901171251371447
Predictive modeling and risk assessment of pancreatic β-cell dysfunction in type 2 diabetes
Wu, N., & Sun, Y. (2025) · Medicine · doi:10.1097/md.0000000000044462
“Inclusion criteria : compliance with the standards set by the American Diabetes Association in the guidelines stipulated in Standards of Medical Care in Diabetes [13] ; all patients were newly diagnosed with T2DM; patients and their families provided informed consent for the study.”
Pawar, A. D., Rohile, S. B., & D., S. S. (2025) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-29628
Malloy, J., & Bird, S. (2025) · Physician Assistant Clinics · doi:10.1016/j.cpha.2025.09.003
Hnamte, L., & Saikia, L. (2025) · Journal of Ecophysiology and Occupational Health · doi:10.18311/jeoh/2025/48111
Graff, F. (2025) · APS EM REVISTA · doi:10.7910/dvn/xfcylr
Asgari, S., Khalili, D., Azizi, F., & Hadaegh, F. (2024) · Figshare · doi:10.6084/m9.figshare.26736105
Nitecki, M., Gerstein, H. C., Balmakov, Y., Tsur, E., Babushkin, V., Michaeli, T., Afek, A., Pinhas-Hamiel, O., Cukierman‐Yaffe, T., & Twig, G. (2024) · Figshare · doi:10.6084/m9.figshare.26635080
Herrera Galárraga, V. E., & Solano Córdova, P. A. (2023) · Repositorio Institucional (Universidad de Cuenca)
Mukonda, E. E. (2025) · Open University of Cape Town (University of Cape Town)
Promoção e educação para a saúde em indivíduos com diabetes tipo 2
Carrão Lopes, M. (2024) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Aberle, J., Lautenbach, A., Meyhöfer, S., Menzen, M., Selig, L., Mai, K., Blüher, M., & Terkamp, C. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2592-8270 · Cited by 2
Filho, A. O. F. M. (2023) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Elucidating Genetic Drivers of Chronic Inflammation in Obesity
Rashidova, L. O., Shashnin, D. D., Zubeev, P. S., Abalikhina, E. P., Podprugina, N. G., Козлов, В. А., Викторович, С. С., Mishchenko, T. A., & Vedunova, M. V. (2026) · Biomedicines · doi:10.3390/biomedicines14020447
“Obesity is a pathological condition that serves as a risk factor for the development and progression of numerous diseases, including type 2 diabetes mellitus, hypertension, steatohepatitis, reproductive dysfunction, and others [1].”
SEA 2026 Standards for Global Control of Vascular Risk
Mostaza, J. M., Pintó, X., Armario, P., Guijarro, C., Masana, L., Real, J. T., Arrobas-Velilla, T., Baeza‐Trinidad, R., Calmarza, P., Cebollada, J., et al. (2026) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2026.500889 · Cited by 3
Ayuso, M. C. (2023) · e_Buah
Ríos, C. P., & Arias, V. A. E. (2024) · Repositorio CES
Aberle, J., Lautenbach, A., Meyhöfer, S., Menzen, M., Selig, L., Mai, K., Blüher, M., & Terkamp, C. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01446-x
Research Progress on the Association between Chronic Diabetes Complications and Adverse Outcomes
Zhu, X.-T. (2026) · Hans Journal of Food and Nutrition Science · doi:10.12677/hjfns.2026.152020
Khawar, M., Baba, A. H., Akhtar, R., Rawat, A., Afzaal, H. B., Haq, A. U., Khalid, M. B., Ghazi, M. A., Awan, J., Kumar, B., et al. (2026) · Nepal Journal of Epidemiology · doi:10.3126/nje.v16i1.92323
“The ADA Standards of Care of 2023 state that weight loss of more than 10% of the body can be disease-modifying and improve or cure the condition of obstructive sleep apnoea, T2DM and hypertension [16].”
Miladi, S. (2024) · theses.fr (ABES) · doi:10.70675/e885d131z8209z4190zb218z9fcdf5db8f98
Dinh, H. C., Bui, T. M., Tran, L. P., Nguyen, T. U. O. N. G., & Vo, N. T. M. (2026) · Romanian Medical Journal · doi:10.37897/rmj.2026.1.18
“In contrast, visceral adiposity, a defining feature of central obesity, has been more closely linked to metabolic disturbances, particularly in individuals with type 2 diabetes [21].”
Shi, H., Li, R., Shang, J., Chen, Z., Zhao, X., Li, S., & Yang, L. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1793094
“While conventional antihypertensive agents remain foundational, their limited impact on glycemia and associated side effects underscore the need for complementary strategies that address both conditions simultaneously (5 – 7).”
Aberle, J., Lautenbach, A., Meyhöfer, S., Menzen, M., Selig, L., Mai, K., Blüher, M., & Terkamp, C. (2026) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2766-3375
Diabetes Complications in Primary Care: Epidemiological Patterns and Associated Factors
de Magalhães, A. C. P. S., Amaral, T. L. M., de Vasconcellos, M. T. L., & Monteiro, G. T. R. (2026) · Diabetology · doi:10.3390/diabetology7060107
“Most participants were ≥ 60 years old, physically inactive, had hypertriglyceridemia, and were obese—a profile strongly linked to DM and its complications [29].”
Silva, G. F. S., Costa, D. S. A., Dias, D. L., Santos, J. N., Palma, A. L. D. R., & do Nascimento, A. B. B. (2026) · Research Society and Development · doi:10.33448/rsd-v15i6.51320
Miličević, T., Cvitković, I., Volčanšek, Š., Katsiki, N., Mikhailidis, D. P., Patoulias, D., & Muzurović, E. M. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2706660
“As in the case with other antiobesity medications, treatment should be discontinued after 12 weeks if BW is not reduced by ≥5% from baseline [38].”
InfluentialHe, W., Yi-di, S., Wang, X., He, S.-Y., Tao, X., Yuan, S.-X., Zhou, L., & Long, E.-W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1889594
“For adults with obesity without diabetes, this dual improvement in weight and metabolism may also help lower the risk of progression to T2DM and cardiovascular disease in the future (ElSayed et al., 2023).”
Chyl, J. R., Kowalewski, Ł., Gutowska, O. B., Nowak, W., Kostuch, W. M., Zimon, A., Styczyńska, M. A., Błażowska, O., Zielnik, M., & Jurewicz, A. (2026) · Quality in Sport · doi:10.12775/qs.2026.70.74691
Hegaz, M. G., Aboud, M. Y. A., Kamel, A. I. I., Naveed, M. A., Elsayad, O. G., & Sorathia, A. Z. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02538-x
“…of titrating to the 36 mg maintenance dose to maximize therapeutic gains, a principle reflected in recent guidelines from the American Association of Clinical Endocrinology (AACE) and the 2023 ADA standards, which recommend GLP-1 RAs for weight management in patients with obesity and T2D [2, 52].”
Weight Management in Epilepsy, a Narrative Review
Burbano, M. C., Abraham, Z., & Burneo, J. G. (2026) · Current Treatment Options in Neurology · doi:10.1007/s11940-026-00893-7
“It is worth noting that the use of phentermine for people with epilepsy is generally not recommended or advised with extreme caution due to increased risk of seizure activity [ 20 ].”
Susilowati, E., & Susanti, E. (2026) · Jurnal Ilmiah Biosaintropis (Bioscience -Tropic) · doi:10.33474/ejbst.v12i1.661
Hoog, M. M., Vallarino, C. R., Maldonado, J. M., Grabner, M., Teng, C., Terrell, K. A., & Richard, E. L. (2026) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2026.32.10.1173
Wang, Y., Liu, Z., Wang, S., Lv, C., El-Seedi, H. R., Khalifa, S. A. M., & Wang, H. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70351
“Contemporary treatment strategies increasingly emphasize durable metabolic control [6], reduction of cardiovascular and renal risk [7, 8], weight management [9] and long-term treatment sustainability [10], rather than short-term glycemic targets alone.”
Ajay Kumar Gupta, A. M., Mishra, A., & Katiyar, P. (2024) · Journal of chemical health risks
Lasari, H. H. D., Nurikhwan, P., Hamka, H., Wahyuni, W., Hendriyono, F., Wahyudi, E., Sakdiah, H., Sonda, S., Hamida, S., & Rasidah, S. (2026) · Jurnal Pengabdian Kepada Masyarakat · doi:10.22146/jpkm.111241
Padagi, J. A., Qorahman, W., & Fatmawati, Z. I. (2026) · Jurnal Ilmiah Dan Karya Mahasiswa · doi:10.54066/jikma.v4i5.4906
“IMT yang tinggi berkaitan dengan peningkatan jaringan adiposa, terutama lemak viseral, yang menurunkan sensitivitas sel terhadap insulin sehingga terjadi resistensi insulin dan hiperglikemia kronis (Elsayed et al ., 2023).”
Jang, R., Jang, M., Ruan, X., Jin, C., & Kim, W. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-026-04199-0
“Ongoing management should include routine assessment of body weight, blood pressure, and treatment-related adverse effects [ 54].”
Metadata
- Authors
- ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., Kahan, S., Khunti, K., Leon, J., Lyons, S. K., Perry, M. L., Prahalad, P., Pratley, R. E., Seley, J. J., Stanton, R. C., Gabbay, R. A., & American Diabetes Association
- ORCID
- ElSayed, Nuha A.
- Aleppo, Grazia
- Aroda, Vanita R.
- Bannuru, Raveendhara R.
- Brown, Florence M.
- Bruemmer, Dennis
- Collins, Billy S.
- Hilliard, Marisa E.
- Isaacs, Diana
- Johnson, Eric L.
- Kahan, Scott
- Khunti, Kamlesh
- Lyons, Sarah K.
- Perry, Mary Lou
- Prahalad, Priya
- Pratley, Richard E.
- Seley, Jane Jeffrie
- Stanton, Robert C.
- Gabbay, Robert A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-12-12
- Volume
- 46
- Issue
- Supplement_1
- Pages
- S128-S139
- ISSN
- 0149-5992 (ISSN-L)
- PMC
- PMC9810466
- OpenAlex
- W4311182596
- Cited by
- 244
- References
- 129
- Citations by year
- 2026: 22 · 2025: 58 · 2024: 95 · 2023: 68
- FWCI
- 7.85
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- obesity, weight management, type 2 diabetes, diabetes prevention, diabetes treatment, clinical guidelines
- MeSH terms
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrinology, Humans, Obesity, Reference Standards, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.